Resverlogix patents to pdf

Whereas in many parts of the world a low protein diet lpd, 0. Treatment of diseases associated with the egr1 enhancer. Assuming 30 trading days horizon, and your above average risk tolerance our recommendation regarding resverlogix corp is strong sell. Associations of chronic inflammation, insulin resistance. Message board online community of active, educated investors researching and discussing resverlogix corp. All i say is imho and not to be construed as investment advice. Detailed price information for resverlogix corp rvxt from the globe and mail including charting and trades. Multiple patents can be downloaded by separating each number with a semicolon. Rvxcf stock, price quote and chart, trading and investing tools. Effect of apabetalone added to standard therapy on major adverse cardiovascular events in patients with recent acute coronary syndrome and type 2. Gene regulatory pathways comprise an emerging and active area of chemical probe discovery and investigational drug development. Google patents is a source where you can browse and search the us patents. Otc us stock quote resverlogix corp bloomberg markets.

Resverlogix receives approval pathway from the fda as to the inclusion of usa patients in the phase 3 betonmace trial. To access over 100 stock metrics like beta, evebitda, pe10, free cash flow yield, kz index and cash conversion cycle. Robust intellectual property position for composition, use, and manufacturing, with patent life ranging from 2027 to. Head office 300, 4820 richard road sw calgary, ab, canada, t3e 6l1 phone 403. Faculty disclosures in accordance with the standards of commercial support of the accreditation council for continuing medical education accme, which require balance, independence, objectivity. Current or planned apabetalone rvx208 clinical trials. Us patent for antiinflammatory agents patent patent. Inhibitors of emerging epigenetic targets for cancer. The intellectual property of resverlogix includes 28 registered patents primarily in the medical or veterinary science. Resverlogixs success in inflammation program results in 2 patents filed novel small molecules illustrate potential cost effective approach for rheumatoid arthritis may 19, 2009 calgary. View realtime stock prices and stock quotes for a full financial overview. Resverlogix corp buy or sell 2020 forecast macroaxis. Latebreaking science abstracts from the american heart associations scientific sessions 2018 and latebreaking abstracts in resuscitation science from the resuscitation science symposium 2018.

Promising directions in atherosclerosis treatment based on. Bet bromodomain inhibition is an epigenetic mechanism that can regulate diseasecausing genes. The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotein ai apoai, and their use for treatment and prevention of cardiovascular. Macroaxis provides resverlogix corp buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding rvxcf positions. Resverlogix announces publication of key apabetalone study betonmace in the journal of the american medical association.

Extended european search report, including supplementary search report and opinion, dated jun. He has a wealth of experience advising national and international clients on. Our patents and patent applications will protect our ideas and inventions related to. To stock quote, history, news and other vital information to help you with your stock trading and investing. So, naturally, once hes got you fretting about a huge gain to come in just a couple days this is the perfect time to say gosh, sorry, cant tell you the details unless you subscribe to. Patent and trademark office, please enter your request in the format. This is the resverlogix patent for cotreatment with rvx208 and rosuvastatin that resverlogix was referring to in their september 20 news release. Bromodomain and extraterminal domain bet inhibitors. Fenofibrate, the most commonly used fibrate in contemporary practice, was introduced in the 1970s. This unique feature results in the different genomewide expression profile. Fibric acid derivatives have been used in cardiovascular medicine for a very long time.

Cholesterol drug rvx208 failed to raise levels of a protein believed to help clear plaque from clogged heart arteries in a midstage trial. Resverlogix corp original assignee resverlogix corp priority date the priority date is an assumption and is not a legal conclusion. Pharmaceutical compositions for substituted quinazolinones. On page 269, there is a blurb on clinical development plan. Additionally, resverlogix has registered 7 trademarks with the most popular class being scientific and technological services. Resverlogixs bet protein inhibitor rvx208 meets primary. The present invention relates to inhibitors of rockl and r0ck2 and methods of modulating the pharmacokinetic andor pharmacodynamic properties of such compounds. To is a clinical stage cardiovascular compan y with an epigenetic platform technology that modulates protein production. The present disclosure also provides, in part, methods of using the pharmaceutical formulations for regulating the expression of apolipoprotein ai apoai, and their use for the treatment and prevention of cardiovascular disease and related disease states, including cholesterol or. Robust intellectual property position for composition, use, and manufacturing, with patent life ranging from. Described are new methods for promoting the expression of apolipoprotein a1 apo a1 for increasing levels of hdl, and assays for screening and identifying compounds for regulating expression of the. Bet inhibitors have been described that are able to discriminate between the first and second bromodomains of bet proteins bd1 vs bd2. Resverlogix inc 44 montgomery st san francisco ca 94104. It is currently being evaluated in a phase 2b clinical trial for its ability to reverse andor stabilize atherosclerotic disease.

A prespecified analysis of the placebocontrolled odyssey outcomes trial in patients with recent acute coronary syndrome acs determined whether alirocumabinduced changes in. Fabrys disease pipeline analysis report covers 20 drugs currently in different phases of development. In june 20, certain chemical scaffold and patents related to research and development under the epigenetic drug development platform were spun off to a newly created company, zenith epigenetics, including exploration of therapeutic options in the areas of cancer and autoimmune diseases. Sen has published several dozen papers in top ranking international journals and authored a book on bone diseases.

Resverlogix is developing apabetalone rvx 208, a first inclass bet inhibition small molecule called apabetalone for the treatment of and efficient. We may not accurately predict the protection afforded by our patents and. Resverlogix corp is canadabased clinicalstage biotechnology company. Toronto including stock price, stock chart, company news, key statistics, fundamentals and company profile. Exact sciences corporation investor relations events. Resverlogixs success in inflammation program results in 2. Ad is quite complex, and it is improbable for any one drug or other intervention to successfully treat it.

The present disclosure relates to novel solid pharmaceutical formulations and process for their preparation. This populationbased cohort study among canadian adults examines how the associations of severe obesity with adverse outcomes may be modified by the presence of systemic. Rvx today announces that it has scheduled a conference call and webcast to supplement the presentation of betonmace results to be made during the. Successful assert trial results in resverlogix filing new. What is the future of bromodomains in targeted drug. Design patents, patent patents, pregrant publications, reissues, and statutory invention registrations are all included. Publication of us10111885b2 publication critical patentus10111885b2en. Share your opinion and gain insight from other stock traders and investors. The failure of a second large phase ii study caused.

Multiple patents can be obtained by separating requests with a semicolon. Current pharmacotherapeutic approaches are based on aiding the sufferers to. May 19, 2009 calgary, ab and atlanta, ga resverlogix corp. Fabrys disease is a rare genetic disorder caused mostly in males than females due to the deficiency of. North american experience with low protein diet for non. He is an inventor on a number of us patents and numerous international patents. Early negotiations for a partnership or buyout could account for the delay. Rvx posted its financial statements and management discussion and analysis for its second quarter of fy.

Rvx208 is a firstinclass, small molecule that inhibits bet bromodomains. Toronto stock quote resverlogix corp bloomberg markets. Sproutly, inc srutf stock message board investorshub. Icmje form for disclosure of potential conflicts of interest. Can someone please tell us if this is known stuff, or whether there is new patents being filed. Resverlogix has been continuously discussing with the fda regarding the clinical development.

Rvx208 is the only selective bet bromodomain inhibitor in clinical trials. Bromodomain and extraterminal domain bet proteins are identified as epigenetic readers and can be characterized by the presence of two tandem bromodomains bd1 and bd2, extraterminal domain. On september 20, 2006 the company announced its name had been. A new patent application has been filed for novel dosing combinations of rvx208 and leading statin therapeutics.

Abstract background experimental and clinical evidence supports the role of inflammation in atherosclerosis and its complications. Intellectual property ip is a generic legal term for patents, s, and trademarks, all of which provide legal rights to protect ideas, the expression of ideas, and the inventors of such. Use of this site is subject to, and your continued use constitutes your express agreement to be bound by, the terms of use and privacy statement. In june 20, certain chemical scaffold and patents related to research and development under the epigenetic drug development platform were spun off to a newly created company, zenith, including. Resverlogix might still be mulling whether its hdlbooster rvx208 has a future, but investors have already made up their minds. Alicia hong focuses her practice on chinarelated corporate transactions in the life sciences industry. The present disclosure also provides, in part, methods of using the pharmaceutical.

This editorial refers to accaha guidelines superior to esceas guidelines for primary prevention with statins in nondiabetic europeans. In particular, our patents and patent applications may be subject to interferences in which the priority of invention may be awarded to a third party. Treatment of diseases associated with the egr1 enhancer element pat cn1925862. Icmje form for disclosure of potential conflicts of interest ballantyne 4 are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of. In june 20, certain chemical scaffold and patents related to research and development under the epigenetic drug development platform were spun off to a newly created company, zenith, including exploration of therapeutic options in the areas of cancer and autoimmune diseases. In fiscal 2012, we were issued five patents within four patent families in. Colchicine is an orally administered, potent antiinflammatory. Us8884046b2 compounds useful in the synthesis of benzamide. The present and future of pharmacotherapy of alzheimers. Resverlogix for the treatment of atherosclerosis 7 and function through inhibition of only second bet bromodomain 8. Apabetalone is the bet inhibitor selective for the. Otc us including stock price, stock chart, company news, key statistics, fundamentals and company profile.

May 23, 2007 if you are searching patents online, then this news will come in handy for you. Entering into the waiver agreement generated cash for resverlogix without impacting on its core assets. Resverlogix rvx208rvx000222 6 trials progressive lymphoma constellation cpi0610 nct01949883 nut midline carcinoma tensha ten010 nct01987362. In june 20, certain chemical scaffold and patents related to research and development under the epigenetic drug development platform were spun off to a newly created company, zenith epigenetics. Exact sciences corporation 441 charmany drive madison, wi 53719 powered by q4 inc. Jan 18, 2017 extended european search report, including supplementary search report and opinion, dated jun. Resverlogix inc 44 montgomery st san francisco, ca. Effect of alirocumab on lipoproteina and cardiovascular. The company is developing apabetalone rvx208, a molecule that is a selective bromodomain and extraterminal bet inhibitor.

Resverlogix s bet protein inhibitor rvx208 meets primary endpoint in sustain clinical trial in patients with high risk cardiovascular disease news provided by resverlogix corp. Every resverlogix warrant holder at the effective date of the arrangement received one warrant in zenith for every warrant held in. Rvx is pleased to announce today that it has filed additional new patent protection based on novel findings derived from its recently completed assert phase 2 clinical trial. Ckd stages 3a and 3b patients, with a history of cvd phase 3 betonmace subgroup high risk ckd patients on dialysis phase 2b betonrenal study. Disclosed are novel compounds that are useful in regulating. Resverlogix receives approval pathway from the fda as to the. Resverlogix is currently investigating the potential for expansion into specific kidney indications. Latebreaking science abstracts from the american heart.

Cardiovascular diseases cvds are the leading cause of death worldwide. Increased synthesis of apolipoprotein ai apoai and hdl is believed to provide a new approach to treating atherosclerosis through the stimulation of reverse cholesterol transport. Whats new resverlogix reports second quarter 2018 results on december 14, resverlogix corp. Get breaking news and analysis on resverlogix corp. Disclosed are novel compounds that are useful in regulating the expression of interleukin6 il6 andor vascular cell adhesion molecule1 vcam1, and their use in the treatment andor prevention of cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed. She advises on crossborder mergers and acquisitions, licensing, codevelopment, strategic alliances, vc. With a number of pending patent applications, we believe we have broad. To announced today the recent publication of an article titled. However, no bet inhibitor has yet been described that. We do not know whether our patents and patent applications would be entitled to priority over patents. A read is counted each time someone views a publication summary such as the title, abstract, and list of authors, clicks on a figure, or views or downloads the fulltext.

328 173 68 1340 805 1416 1080 553 345 1118 545 718 464 1219 603 506 478 1304 795 1044 1261 259 1346 567 583 261 1051 407 1441 4 1457 87 34 1221 521 1009 242